We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Ticker | Name | Price | Change | Change % | Volume | Trades |
---|---|---|---|---|---|---|
DSE | Dropsuite Limited | 2.79 | 2.52 | 914.55% | 7,656 | 12 |
SGAO | Sarytogan Graphite Ltd | 0.026 | 0.009 | 52.94% | 102,550 | 3 |
WEL | Winchester Energy Ltd | 0.003 | 0.001 | 50.00% | 729,384 | 3 |
VPR | Volt Power Group Limited | 0.0015 | 0.0005 | 50.00% | 50,500 | 1 |
BASO | Bass Oil Limited | 0.003 | 0.001 | 50.00% | 700,000 | 2 |
APC | Australian Potash Limited | 0.0015 | 0.0005 | 50.00% | 138,000 | 5 |
FRSO | Forrestania Resources Ltd | 0.003 | 0.001 | 50.00% | 321,500 | 2 |
ICLO | Iceni Gold Limited | 0.019 | 0.006 | 46.15% | 678,830 | 4 |
IIQ | Inoviq Ltd | 0.655 | 0.19 | 40.86% | 4,375,244 | 963 |
GGE | Grand Gulf Energy Limited | 0.007 | 0.002 | 40.00% | 5,345,080 | 23 |
ECT | Environmental Clean Technologies Limited | 0.004 | 0.001 | 33.33% | 740,655 | 8 |
NEW YORK and SHENZHEN, China, May 31, 2024 /PRNewswire/ -- MingZhu Logistics Holdings Limited ("MingZhu" or the "Company") (Nasdaq: YGMZ), an elite provider of logistics and transportation services to businesses, today announced it has agreed to acquire Oxylus Global Inc ("Oxylus")., as part of its continued aggressive business diversification and growth acceleration strategy. The closing of the all-stock acquisition is subject to customary closing conditions, including regulatory approvals, and is expected to be completed by the end of calendar year 2024.
Waste Management, Inc. (NYSE: WM) and Stericycle (NASDAQ: SRCL) announced today that they have entered into a definitive agreement under which WM will acquire all outstanding shares of Stericycle for $62.00 per share in cash, representing a total enterprise value of approximately $7.2 billion when including approximately $1.4 billion of Stericycle’s net debt. The per share price represents a premium of 24% to Stericycle’s 60-day volume weighted average price as of May 23, 2024, which was the last trading day before an article reported that Stericycle was considering a potential sale.
Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that the Company received and accepted an unsolicited offer from an institutional investor to purchase 22,222,222 shares of the Company’s common stock at $9.00 per share, a premium to the closing price on Friday, May, 31, 2024, for aggregate gross proceeds to the Company of approximately $200.0 million.
Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company developing an innovative drug delivery technology designed to leverage a patient’s own biology to deliver rare disease therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for its EryDex System for the treatment of patients with Ataxia-Telangiectasia (A-T). EryDex is comprised of dexamethasone sodium phosphate (DSP) encapsulated in a patient’s own red blood cells utilizing Quince’s proprietary Autologous Intracellular Drug Encapsulation (AIDE) technology platform. DSP is a corticosteroid well known for its anti-inflammatory properties as well as its dose-limiting toxicity due to adrenal suppression. ...
Ticker | Name | Price | Change | Change % | Market Cap | Volume |
---|---|---|---|---|---|---|
BTC | Bitcoin | 69,141.03 | 1,392.62 | 2.06% | 1.36T | 2,913,452,861 |
ETH | Ethereum | 3,810.37 | 30.51 | 0.81% | 457.53B | 1,501,958,114 |
BNB | Binance Coin | 634.00 | 31.38 | 5.21% | 99.64B | 379,445,174 |
USDT | Tether USD | 0.99965 | 0.00019 | 0.02% | 97.81B | 101,850,578 |
SOL | Solana | 165.25 | 2.19 | 1.34% | 72.67B | 624,814,501 |
STETH | stETH | 3,807.12 | 29.53 | 0.78% | 37.33B | 5,423,603 |
XRP | Ripple | 0.5192 | 0.0058 | 1.13% | 28.3B | 198,990,899 |
USDC | USD Coin | 1.00 | 0.0001 | 0.01% | 28.07B | 408,901,391 |
DOGE | Dogecoin | 0.1618 | 0.00464 | 2.95% | 23.13B | 227,320,298 |
TONCOIN | Wrapped TON Coin | 6.62 | -0.191807 | -2.82% | 22.95B | 223,964,592 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions